

Amendments to the Specification:

Please amend the Specification as follows:

On page 3, paragraph 10, please amend the first sentence as follows:

[10] Demegen, Inc. of Pittsburg, PA owns several peptides which are being developed for medical use. One is D2A21 (FAKKFAKKFKKFAKKFAKFAFAF) (SEQ. ID. No. ~~57~~ 65) being developed under the trade name DEMEGEL.™

On page 7, paragraph 28, please amend the last sentence as follows:

Positive controls included non-periodic antimicrobial peptides D2A21 (FAKKFAKKFKKFAKKFAKFAFAF) (Seq. ID. No. ~~57~~ 65) and D4E1 (FKLRAKIKVRLRAKIKL) (SEQ. ID. No. ~~58~~ 66).

On page 8, paragraph 30, Table 2, please replace the column labeled SEQ. ID. NO. with the following:

SEQ ID NO
65
57
58
59
1
2
3
4

On page 9, paragraph 32, Table 3, please replace the column labeled SEQ. ID. NO. with the following:

SEQ ID NO
65
66

57
58
59
1
2
3
4
5
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
25
26
27
28
29
35

36
37
38
39
60
44
45
46
47
48
51
52
53
67
68
69

On page 11, paragraph 38, Table 4, please replace the column labeled SEQ. ID. NO. with the following:

SEQ ID NO
65
66
57
58
59
1
2
3

Appl. No. 10/785,210
Amendment dated January 17, 2006
Reply to Office Action of August 15, 2005

4
5
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
25
26
27
28
29
35
36
37
38
39
60
44

45
46
47
48
51
52
53

On page 15, paragraph 51, Table 6, please replace the column labeled SEQ. ID. NO. with the following:

SEQ ID NO
5
6
7
61
23
19
9
10
11
12
13
14
15
16
17
18
20

Appl. No. 10/785,210
Amendment dated January 17, 2006
Reply to Office Action of August 15, 2005

22
62
63
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
60
44
45
46
47
48
49
50

Appl. No. 10/785,210
Amendment dated January 17, 2006
Reply to Office Action of August 15, 2005

51
52
53
64
54
55
56

Please insert the substituted sequence listing after the specification and before the claims. The substituted sequence listing contains 21 pages.